Merck says U.S. Patent No. 7,326,708 covers the sitagliptin salt in Januvia and expires on November 24, 2026 [1]. Settlements
Patent Expiration Is a Trigger. What You Really Need Is the Opportunity Behind It. Read Post »
Humira had U.S. net revenues of $21.237 billion in 2022. [1] It made up about 37% of AbbVie’s total net
Loss of Exclusivity vs. Patent Expiration: Track the Date That Moves Revenue Read Post »
I-MAK counts 257 U.S. patent applications and 130 granted U.S. patents on Humira (adalimumab) [1]. In its 2016 BPCIA suit
On December 10, 2025, Teva asked FDA to remove more than 200 patent listings from the Orange Book. [1] The
Biopharma companies announced $130 billion of acquisitions in the first half of 2026. That is about 98% of the $133
From Patent Cliff to Partnership Pipeline: A 7-Step Framework Built on 2026 Deal Data Read Post »
A small-molecule drug approved in 1990 had 2.1 FDA-listed patents on average. A drug approved in 2019 had 6.9 [1].
Drug Patent Portfolios More Than Tripled Since 1990. Here Is What Changed Read Post »
Johnson & Johnson’s Stelara sales fell 59.7% year over year in the first quarter of 2026, to $656 million, after
On August 13, 2026, the rules governing “zombie patent” revivals get tighter. The U.S. Patent and Trademark Office finalized a
In September 2025, the FDA sent more than 50 warning letters to compounding pharmacies and telehealth sellers of semaglutide and
Sign in or create a free account to read this DrugPatentWatch article
